MedTrace Logo

Paricipant Preferences in the Treatment of Inflammatory Bowel Disease (IBD) in Europe

NCT04597905 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 686

Last updated 2021-02-11

No results posted yet for this study

Summary

The purpose of this survey is to describe Crohn's disease (CD) participants' as well as ulcerative colitis (UC) participants' preferences towards the attributes of treatment with advanced therapies for IBD, including safety and efficacy profiles, frequency and route of administration (RoA) in a real-world setting.

Conditions

  • Crohn Disease
  • Colitis, Ulcerative
  • Inflammatory Bowel Diseases

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Takeda

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-21
Primary Completion
2021-01-31
Completion
2021-01-31

Countries

  • France

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04597905 on ClinicalTrials.gov